Allucent, a prominent global mid-sized clinical research organization (CRO), has been designated by the Biomedical Advanced Research and Development Authority

Zhiyi Biotech has announced the initiation of the U.S. Phase 1 clinical trial for their innovative product SK10, which is aimed at addressing Chemotherapy-induced Diarrhea (CID). The trial marks a significant milestone as the first three subjects have been successfully dosed. SK10 is a heat-killed Bacteroides fragilis product developed by Zhiyi Biotech.

Altogen Labs, a preclinical Contract Research Organization (CRO) laboratory, has announced the successful validation of a comprehensive array of 10 lung cancer xenograft models.

MapLight Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of targeted therapeutics for brain disorders, has successfully completed a second Phase 1 clinical trial assessing the safety and efficacy of ML-007, a novel M1/M4 muscarinic receptor agonist.

Everest Medicines, a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative medicines and vaccines, has announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region, China, has accepted its New Drug Application (NDA) for Nefecon®.

SimBioSys, a pioneering TechBio company leveraging Artificial Intelligence (AI), spatial biophysics, and data science to redefine precision medicine and combat cancer, proudly announces its role as one of the founding members of the CancerX initiative.

AGC Biologics, a prominent global biopharmaceutical contract development and manufacturing organization (CDMO), has unveiled the expansion of its Longmont, Colorado facility with the addition of three state-of-the-art Grade B cell therapy manufacturing facilities.

Paradigm Therapeutics Inc., a biopharmaceutical company, has successfully finalized the acquisition of the global rights for SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. The specifics of the agreement have not been publicly disclosed.

LEO Pharma has officially announced a strategic move to acquire Timber Pharmaceuticals, Inc., a company listed on the NYSE American under the ticker symbol TMBR.

Enveric Biosciences (NASDAQ: ENVB), a biotech firm dedicated to pioneering innovative neuroplastogenic small-molecule therapeutics aimed at addressing anxiety, depression, and addiction disorders, has recently achieved a significant milestone.